CP-28888 (CP 28888-27)
(Synonyms: CP 28888-27) 目录号 : GC32262CP-28888 (CP 28888-27) 是一种干扰素诱导剂,对小鼠更有效,但对人的活性较低且没有抗鼻病毒作用。
Cas No.:69938-75-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
CP-28888 is an interferon inducer, more potent in mice, but is less active in man and devoid of antirhinovirus effects.
CP-28,888-27 appears to be a more potent interferon inducer than CP-20,961 in experiments using comparable methods in animal systems. In CP-28,888-27 (25 mg/kg, i.p.)-treated mice, plasma interferon levels of CP-28,888-27 are 10-fold higher than CP-20,961[1].
[1]. Douglas RG Jr, et al. Lack of effect of an interferon inducer, N,N-dihexadecyl-m-xylylenediamine, on rhinovirus challenge in humans. Antimicrob Agents Chemother. 1979 Feb;15(2):269-72.
Cas No. | 69938-75-6 | SDF | |
别名 | CP 28888-27 | ||
Canonical SMILES | CCCCCCCCCCCCCCCCNCC1=CC(CNCCCCCCCCCCCCCCCC)=CC=C1 | ||
分子式 | C40H76N2 | 分子量 | 585.04 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7093 mL | 8.5464 mL | 17.0928 mL |
5 mM | 0.3419 mL | 1.7093 mL | 3.4186 mL |
10 mM | 0.1709 mL | 0.8546 mL | 1.7093 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Lack of effect of an interferon inducer, N,N-dihexadecyl-m-xylylenediamine, on rhinovirus challenge in humans
Antimicrob Agents Chemother 1979 Feb;15(2):269-72.PMID:371545DOI:PMC352645
CP-28,888-27 and placebo nasal sprays were compared in 62 normal volunteers challenged with rhinovirus type 13 or 21 in two randomized, double-blind studies. Half of the subjects received CP-28,888-27 and half received nasal placebo administered at 24, 20, and 16 h before challenge and 4 and 8 h after challenge. In each study, the number of subjects shedding virus in nasal washes, the number developing fourfold or greater serum antibody responses, and the number developing afebrile or febrile upper respiratory tract illness were not significantly different comparing subjects given CP-28,888-27 and those given placebo. Interferon was detected in nasal washes from 5 of 15 volunteers tested in the CP-28,888-27 group compared to 2 of 15 volunteers from the placebo group.